All TEM8 articles
-
NewsTrial tests virus-immunotherapy combination for neuroendocrine tumors
A phase I clinical trial is testing whether a tumor-targeting virus can help immunotherapy work more effectively against aggressive neuroendocrine tumors that often resist treatment. The ongoing study has completed its first three dose levels with no severe treatment-related side effects reported to date.